scholarly journals Multicenter Validation of Cyclin D1, MCM7, TRIM29, and UBE2C as Prognostic Protein Markers in Non-Muscle–Invasive Bladder Cancer

2013 ◽  
Vol 182 (2) ◽  
pp. 339-349 ◽  
Author(s):  
Niels Fristrup ◽  
Karin Birkenkamp-Demtröder ◽  
Thomas Reinert ◽  
Marta Sanchez-Carbayo ◽  
Ulrika Segersten ◽  
...  
2012 ◽  
Vol 180 (5) ◽  
pp. 1824-1834 ◽  
Author(s):  
Niels Fristrup ◽  
Benedicte P. Ulhøi ◽  
Karin Birkenkamp-Demtröder ◽  
Francisco Mansilla ◽  
Marta Sanchez-Carbayo ◽  
...  

2012 ◽  
Author(s):  
Niels Fristrup ◽  
Benedicte Parm Ulhøi ◽  
Karin Birkenkamp-Demtröder ◽  
Francisco Mansilla ◽  
Marta Sanchez-Carbayo ◽  
...  

Nanomaterials ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 2384
Author(s):  
Benito Blanco Gómez ◽  
Rubén López-Cortés ◽  
Francisco Javier Casas-Nebra ◽  
Sergio Vázquez-Estévez ◽  
Daniel Pérez-Fentes ◽  
...  

Because cystoscopy is expensive and invasive, a new method of detecting non-invasive muscular bladder cancer (NMIBC) is needed. This study aims to identify potential serum protein markers for NMIBC to improve diagnosis and to find treatment approaches that avoid disease progression to a life-threatening phenotype (muscle-invasive bladder cancer, MIBC). Here, silver nanoparticles (AgNPs, 9.73 ± 1.70 nm) as a scavenging device together with sequential window acquisition of all theoretical mass spectra (SWATH-MS) were used to quantitatively analyze the blood serum protein alterations in two NMIBC subtypes, T1 and Ta, and they were compared to normal samples (HC). NMIBC’s analysis of serum samples identified three major groups of proteins, the relative content of which is different from the HC content: proteins implicated in the complement and coagulation cascade pathways and apolipoproteins. In conclusion, many biomarker proteins were identified that merit further examination to validate their useful significance and utility within the clinical management of NMIBC patients.


2020 ◽  
Author(s):  
Dalia Rifaat Al-sharaky ◽  
Moshira Mohammed Abdelwahed ◽  
Hend Ahmad Abdou Kassem ◽  
Abdelnaby Saied Abdelnaby

Abstract BackgroundIn Egypt, Urinary bladder carcinoma is a common malignancy accounting for 14.3% of total malignancies in both sexes with 3:1 male to female ratio. It comprises 88.3% of the total urinary system tumors. To reduce bladder cancer morbidity and mortality there is an urgent need to identify novel tumor marker which are specific enough for prognosis and can serve as effective anticancer targets .Therefore the purpose of this study is to evaluate the role of TROP2, CYCLIN D1, FOXP3 and their relationship with the established clinico-pathological parameters and overall survival of bladder cancer in Egyptian patientsMethodsUsing the standard immunohistochemical technique, TROP2, CYCLIN D1 and FOXP3 expression in 80 primary bladder carcinomas and 20 specimens as non neoplastic group were assessed. The bladder carcinoma cases included 50 cases with muscle invasive bladder cancer and 30 cases with non-muscle invasive bladder cancer ResultsOverexpression of both TROP2 and FOXP3 implied poor prognostic impact as significantly associated with muscle invasive bladder cancer, high grade, advanced stage, lymph node involvement and high mitotic count. Cyclin D1 displayed an inverse relation with both TROP2 and FOXP3 reflecting a favorable prognostic impact. Tumoral FOXP3 expression is directly correlated with peritumoral FOXP3+ lymphocytes expression. TROP2, CYCLIN D1, FOXP3 expression didn’t affect the overall survival of the studied sample.ConclusionsThe inverse relation between Cyclin D1 and TROP2 proposes consumption of Cyclin D1 by TROP2 as a ligand in the urinary bladder carcinogenesis. Strong diffuse overexpression of both TROP2, and FOXP3 could be promising potential biomarkers for identifying patients with poor prognostic factors in bladder cancer serving as potential targets for cancer therapy.


Author(s):  
Jessica Marinaro ◽  
Alexander Zeymo ◽  
Jillian Egan ◽  
Filipe Carvalho ◽  
Ross Krasnow ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document